(VEEV) Veeva Systems - Ratings and Ratios
Cloud CRM, Data, Clinical, Regulatory
VEEV EPS (Earnings per Share)
VEEV Revenue
Description: VEEV Veeva Systems September 29, 2025
Veeva Systems Inc. (NYSE: VEEV) delivers cloud-based software solutions tailored to the life-sciences sector across North America, Europe, APAC, the Middle East, Africa, and Latin America. Its flagship offering, the Veeva Commercial Cloud, bundles the Vault CRM Suite for pharma and biotech firms, Veeva Medical for multi-channel medical content, PromoMats for digital asset management, and Crossix for brand-level analytics.
The Veeva Data Cloud adds OpenData (customer reference data), Link (deep data integration), Compass (de-identified longitudinal patient data), and CRM Pulse (multichannel engagement metrics). The Veeva Development Cloud supports clinical trial execution (Clinical Platform, Clinical Data Management), safety and regulatory processes (Safety, RIM), and the Quality Cloud serves both life-sciences and consumer-products companies. Veeva also provides Business Consulting and a suite of professional services ranging from implementation to ongoing managed services.
Founded in 2007 (originally Verticals onDemand) and headquartered in Pleasanton, California, Veeva has become the de-facto SaaS provider for pharma, commanding a market-share advantage in a sector where cloud adoption is projected to grow at ~15% CAGR through 2028.
Key performance indicators from FY 2023 show total revenue of $2.1 billion, a 22% year-over-year increase, and an operating margin of roughly 30%; subscription-based ARR grew 26% YoY and the company reports a net-retention rate above 95%, underscoring strong customer stickiness.
Macro-level drivers include rising global R&D spend, heightened regulatory scrutiny that favors compliant cloud platforms, and the broader digital transformation of drug discovery, clinical trials, and commercial operations.
For a deeper dive into VEEV’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-driven overview.
VEEV Stock Overview
| Market Cap in USD | 47,779m |
| Sub-Industry | Health Care Technology |
| IPO / Inception | 2013-10-16 |
VEEV Stock Ratings
| Growth Rating | 60.6% |
| Fundamental | 77.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 17.2% |
| Analyst Rating | 3.88 of 5 |
VEEV Dividends
Currently no dividends paidVEEV Growth Ratios
| Growth Correlation 3m | 61.3% |
| Growth Correlation 12m | 83% |
| Growth Correlation 5y | -14.5% |
| CAGR 5y | 15.91% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.59 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.75 |
| Sharpe Ratio 12m | 0.13 |
| Alpha | 18.22 |
| Beta | 0.982 |
| Volatility | 30.70% |
| Current Volume | 773.4k |
| Average Volume 20d | 816.1k |
| Stop Loss | 282.4 (-3%) |
| Signal | 1.05 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (809.9m TTM) > 0 and > 6% of Revenue (6% = 178.1m TTM) |
| FCFTA 0.17 (>2.0%) and ΔFCFTA 1.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 193.4% (prev 167.0%; Δ 26.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 1.35b > Net Income 809.9m (YES >=105%, WARN >=100%) |
| Net Debt (-1.84b) to EBITDA (839.2m) ratio: -2.20 <= 3.0 (WARN <= 3.5) |
| Current Ratio 5.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (167.3m) change vs 12m ago 1.65% (target <= -2.0% for YES) |
| Gross Margin 75.59% (prev 73.35%; Δ 2.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.43% (prev 40.65%; Δ 0.77pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.17 (EBITDA TTM 839.2m / Interest Expense TTM -252.2m) >= 6 (WARN >= 3) |
Altman Z'' 10.03
| (A) 0.72 = (Total Current Assets 6.99b - Total Current Liabilities 1.26b) / Total Assets 8.00b |
| (B) 0.49 = Retained Earnings (Balance) 3.88b / Total Assets 8.00b |
| (C) 0.11 = EBIT TTM 799.4m / Avg Total Assets 7.17b |
| (D) 2.85 = Book Value of Equity 3.88b / Total Liabilities 1.36b |
| Total Rating: 10.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 77.56
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 3.20% = 1.60 |
| 3. FCF Margin 44.74% = 7.50 |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda -2.20 = 2.50 |
| 6. ROIC - WACC (= 0.32)% = 0.40 |
| 7. RoE 13.40% = 1.12 |
| 8. Rev. Trend 97.56% = 7.32 |
| 9. EPS Trend 82.45% = 4.12 |
What is the price of VEEV shares?
Over the past week, the price has changed by +2.17%, over one month by -2.85%, over three months by +3.03% and over the past year by +34.54%.
Is Veeva Systems a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VEEV is around 268.55 USD . This means that VEEV is currently overvalued and has a potential downside of -7.78%.
Is VEEV a buy, sell or hold?
- Strong Buy: 12
- Buy: 7
- Hold: 11
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the VEEV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 320.6 | 10.1% |
| Analysts Target Price | 320.6 | 10.1% |
| ValueRay Target Price | 302.6 | 3.9% |
VEEV Fundamental Data Overview October 25, 2025
P/E Trailing = 59.8563
P/E Forward = 35.3357
P/S = 16.0969
P/B = 7.4266
P/EG = 1.3872
Beta = 0.982
Revenue TTM = 2.97b USD
EBIT TTM = 799.4m USD
EBITDA TTM = 839.2m USD
Long Term Debt = 85.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.7m USD (from shortTermDebt, last quarter)
Debt = 85.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.84b USD (from netDebt column, last quarter)
Enterprise Value = 41.46b USD (47.78b + Debt 85.4m - CCE 6.40b)
Interest Coverage Ratio = -3.17 (Ebit TTM 799.4m / Interest Expense TTM -252.2m)
FCF Yield = 3.20% (FCF TTM 1.33b / Enterprise Value 41.46b)
FCF Margin = 44.74% (FCF TTM 1.33b / Revenue TTM 2.97b)
Net Margin = 27.29% (Net Income TTM 809.9m / Revenue TTM 2.97b)
Gross Margin = 75.59% ((Revenue TTM 2.97b - Cost of Revenue TTM 724.5m) / Revenue TTM)
Gross Margin QoQ = 75.26% (prev 77.10%)
Tobins Q-Ratio = 5.18 (Enterprise Value 41.46b / Total Assets 8.00b)
Interest Expense / Debt = 35.40% (Interest Expense 30.2m / Debt 85.4m)
Taxrate = 24.52% (65.1m / 265.4m)
NOPAT = 603.4m (EBIT 799.4m * (1 - 24.52%))
Current Ratio = 5.57 (Total Current Assets 6.99b / Total Current Liabilities 1.26b)
Debt / Equity = 0.01 (Debt 85.4m / totalStockholderEquity, last quarter 6.64b)
Debt / EBITDA = -2.20 (Net Debt -1.84b / EBITDA 839.2m)
Debt / FCF = -1.39 (Net Debt -1.84b / FCF TTM 1.33b)
Total Stockholder Equity = 6.05b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.12% (Net Income 809.9m / Total Assets 8.00b)
RoE = 13.40% (Net Income TTM 809.9m / Total Stockholder Equity 6.05b)
RoCE = 13.04% (EBIT 799.4m / Capital Employed (Equity 6.05b + L.T.Debt 85.4m))
RoIC = 9.98% (NOPAT 603.4m / Invested Capital 6.05b)
WACC = 9.66% (E(47.78b)/V(47.86b) * Re(9.63%) + D(85.4m)/V(47.86b) * Rd(35.40%) * (1-Tc(0.25)))
Discount Rate = 9.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.07%
[DCF Debug] Terminal Value 74.87% ; FCFE base≈1.19b ; Y1≈1.35b ; Y5≈1.88b
Fair Price DCF = 150.0 (DCF Value 24.58b / Shares Outstanding 163.9m; 5y FCF grow 16.66% → 3.0% )
EPS Correlation: 82.45 | EPS CAGR: 22.85% | SUE: 1.52 | # QB: 12
Revenue Correlation: 97.56 | Revenue CAGR: 13.85% | SUE: 2.02 | # QB: 7
Additional Sources for VEEV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle